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the operating principles and protocols for collection, retention,
retrieval, and analysis of demographic information, signs and
symptoms—including laboratory ﬁndings—and the response to
enzyme replacement therapy with agalsidase alfa in patients with
a conﬁrmed diagnosis of Fabry disease. RESULTS: As of Decem-
ber 2007, 190 centres have enrolled 1453 patients from 19
countries worldwide (754 females, 699 males). Of these, 133 are
girls and 118 boys less than 18 years of age. Data from these
patients have added signiﬁcantly to our understanding of Fabry
disease, with 24 peer-reviewed publications describing the pre-
treatment characteristics of the disease and the response to
agalsidase alfa. Problems encountered include: 1) incomplete
ascertainment of patients with different manifestations of Fabry
disease; 2) some systematic lacunae in the data; and 3) uncer-
tainty about the quality of some data. Progress has been made in
overcoming these problems by: 1) convening regular meetings of
investigators to review protocols, data collection, and ﬁndings
from data analysis; 2) focusing on ‘core data’; 3) concentrating
on achieving comprehensive data collection from centres where
enrolment is especially high; and 4) employing clinical research
associates to increase data collection and ensure data quality.
CONCLUSIONS: FOS has contributed signiﬁcantly to the
understanding of the clinical features of Fabry disease in patients
of all ages. Problems with data collection and quality have been
addressed by a multi-faceted approach, including focusing on a
core panel of data to be collected, together with the use of clinical
research associates to check data completeness and quality.
PND3
TRENDS INTHE PREVALENCE OF AUTISM SPECTRUM
DISORDERS AND RELATED HEALTH CARE UTILIZATION AND
COSTS IN A STATE MEDICAID PROGRAM
Khanna R, Madhavan SS
West Virginia University, Morgantown,WV, USA
OBJECTIVE: Over the past decade, there has been a tremendous
increase in the prevalence of autism spectrum disorders (ASD) in
the United States. With increasing ASD prevalence, the health
care utilization and costs associated with these neurodevelop-
mental disabilities are also expected to increase. The purpose of
this study is to determine the trends in the prevalence of ASD and
ASD-related health care utilization and costs among recipients
enrolled in a state Medicaid program. METHODS: A retrospec-
tive descriptive analysis of a state Medicaid fee-for-service
administrative claims dataset was conducted. Medical services
claims with a primary, secondary, or tertiary diagnosis code of
ASD (ICD-9-CM 299.0/299.8) were extracted to determine the
prevalence of ASD. Claims for psychotropic medications
prescribed to recipients with ASD were then extracted using
de-identiﬁed unique recipient numbers obtained from the
medical services claims. Prevalence and health care utilization
numbers and rates were reported by demographic categories.
Costs were reported from the state Medicaid perspective.
RESULTS: Between 1996 and 2003, the number of recipients
identiﬁed with ASD increased from 246 to 1399, respectively. In
terms of age distribution, recipients in the age group 6–14 years
represented the highest proportion in all the study years, with the
proportion increasing from 38.6% in 1996 to 47.0% in 2003. A
majority of the recipients with ASD were males, who made
69.1% of the sample in 1996 and 74.6% in 2003. Whites con-
stituted a majority (>90%) with respect to ethnicity in all the
study years. The increase in the prevalence of ASD was accom-
panied by an increase in ASD-related health care utilization and
costs. CONCLUSION: Similar to national trends, the prevalence
of ASD increased considerably over the years in the state Med-
icaid program. In addition, the prevalence of ASD among Med-
icaid recipients varied by demographic characteristics. The study
provides useful data to better serve the needs of this growing
population.
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OBJECTIVES: Few studies have evaluated trends among inpa-
tients with cystic ﬁbrosis. The purpose of this paper is to explore
patient demographics, diagnosis, and procedures to gather a
general picture of cystic ﬁbrosis treatment. Exploration of the
cystic ﬁbrosis data set to ﬁnd trends among the variables, race,
gender, mortality, total charges, length of stay, age diagnosis, and
procedures provides insight into better methods to treat indi-
viduals with cystic ﬁbrosis. METHODS: The data used were
taken from the National Inpatient Sample (NIS). The cystic
ﬁbrosis data set was formed by isolating the NIS patients diag-
nosed with cystic ﬁbrosis, using a 10% sample from 2004. The
cystic ﬁbrosis data set contained 1582 observations. Descriptive
statistics were used to examine the data; chi-square tests and
logistic regressions were employed to analyze the data.
RESULTS: Statistics showed that patients with a longer length of
stay were more likely to die during hospitalization and to be
older. Most races had two high density ages; one around 20
years of age and the other around 60 years of age with the
exception of African Americans and Native Americans. The
three procedures: transfusion of packed cells (ICD-9 99.04),
continuous ventilation <96 consecutive hours (ICD-9 96.71),
and endotracheal tube insertion (ICD-9 96.04) and two diag-
noses pneumonia (ICD-9 486) and amyloidosis (ICD-9 277.3,
accumulate deposits of abnormal proteins) were found to be
directly related to mortality. The data also showed that none of
the patients with esophageal reﬂux (ICD-9 530.81) died during
hospitalization. CONCLUSIONS: From the results, older
patients, patients with long lengths of stay, or those diagnosed
with amyloidosis could be considered high-risk for hospital mor-
tality. However, these results are limited; no information about
outpatient factors, medications, or test results could be assessed.
Also, there were few patients who died during hospitalization on
which to base the analysis.
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OBJECTIVE: To assess the rate of substance abuse among
insomnia patients prescribed nonbenzodiazepine receptor
agonists (nBZRAs), benzodiazepines (BZDs), and melatonin
receptor agonists (MRAs). METHODS: This analysis used a
retrospective matched cohort design with data from Florida
Medicaid recipients 18 to 64 years old. Patients initiating
nBZRA, BZD, or MRA therapy between July 1, 2002 and March
31, 2006, without a history of substance abuse, were included in
this analysis. One MRA patient was matched to three nBZRA
and three BZD patients based n demographic and clinical
(history of insomnia, depression, anxiety) characteristics. Service
dates and days of medication supply variables from pharmacy
claims established periods of treatment exposure, while sub-
stance abuse related to sedatives and hypnotics was identiﬁed
using International Classiﬁcation of Diseases 9th edition Clinical
Modiﬁcation (ICD-9-CM) codes for the same time frame. Rates
of substance abuse (SA) were calculated as the number of
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